Related Experiment Video
Updated: Aug 6, 2026

Collection and Extraction of Occupational Air Samples for Analysis of Fungal DNA
Published on: May 2, 2018
Occupational asthma in sawmills of eastern Canada and United States
Abstract:
Eleven individuals with a history of work-related asthma are described. They were employed in 10 different sawmills of northwestern and southeastern Quebec and Maine where coniferous trees (spruces, firs, and pines) are cut into boards. Duration of exposure and symptomatology varied from 1.5 to 40 years and 0.5 to 10 years, respectively. Ten subjects were atopic and seven demonstrated immediate skin reactivity to mixed tree pollens. The diagnosis of occupational asthma was confirmed by significant and sustained changes in serial peak expiratory flow rates at work as compared with a period off work in every individual and significant changes in bronchial responsiveness to histamine at work as compared with a period off work in eight individuals or significant changes in FEV1 at work in the three other subjects. Specific inhalation tests by exposing four workers to sawdust in our laboratory were negative. We conclude that working in this specific type of sawmills of eastern Canada and northeastern United States can cause occupational asthma. Although the causative agent is unknown, the presence of atopy and/or immediate skin reactivity to tree pollens and/or bronchial hyperresponsiveness might be risk factors.
Related Concept Videos
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Other Pulmonary Disorders
Asthma-I: Introduction
Asthma-III: Symptoms and Complications
Classification of Asthma
Lumber
Initially, the surfaces of these lumber pieces are rough, and their dimensions may vary slightly from one end to...
Asthma III: Clinical Manifestations

